

**CANscript™ Predicts Response to Physician-selected Therapies**

**CLINICAL HISTORY**

- 49-year-old woman
- Stage 3 Recurrent Head and Neck Squamous Cell Carcinoma
- Refractory to previous treatments
- Physician faced with multiple treatment options

**Treatments Tested**


**M-Score**

In order of physician preference:

<b>Tx1</b>	cisplatin + docetaxel+ 5-FU	<b>77</b>
<b>Tx2</b>	cetuximab	<b>20</b>
<b>Tx3</b>	cisplatin + erlotinib + 5-FU	<b>68</b>
<b>Tx4</b>	carboplatin+ paclitaxel	<b>70</b>
<b>Tx5</b>	erlotinib	<b>18</b>
<b>Tx6</b>	nimotuzumab	<b>20</b>
<b>Tx7</b>	temsirolimus + cetuximab	<b>28</b>
<b>Tx8</b>	bevacizumab	<b>43</b>

An M-Score of 26 or above predicts clinical response to selected treatment.

**CANscript Results**




**TREATMENT**

- Physician's number one treatment, cisplatin + docetaxel + 5FU, returned an M-Score of 77
- Physician treated patient with Tx4 (carboplatin + paclitaxel), second-highest M-Score at 70
- Decision was made based on high toxicity associated with Tx1

**PATIENT OUTCOME**

Post treatment of Tx4, carboplatin + paclitaxel, clinical and CT evaluation showed a complete response.



Pre-treatment

Post six cycles of treatment